Esketamine Nasal Spray versus Quetiapine for Resistant Depression

被引：0
|
作者：
Horowitz, Mark A. [1 ]
Ploederl, Martin [2 ]
Naudet, Florian [3 ]
机构：
[1] North East London NHS Fdn Trust, London, England
[2] Paracelsus Med Univ Salzburg, Salzburg, Austria
[3] Univ Rennes, Rennes, France
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2024年 / 390卷 / 01期
关键词：
AORTIC-STENOSIS; RATING-SCALE; TRIALS; ANTIDEPRESSANT;
D O I：
10.1056/NEJMc2313230
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In their article on the ESCAPE-TRD trial, Reif et al. (Oct. 5 issue)1 report on the efficacy and safety of esketamine nasal spray in comparison with extended-release quetiapine therapy in patients with treatment-resistant depression. The between-group differences in the change from baseline in the score on the Montgomery-angstrom sberg Depression Rating Scale (MADRS; scores range from 0 to 60, with higher scores indicating more severe depression) at 8 weeks (-2.8 points, favoring esketamine) and 32 weeks (-2.2 points, also favoring esketamine) were significant but were less than the minimum clinically important difference.2 The data on remission that were . . .
引用
收藏
页码：93 / 93
页数：1
相关论文
共 50 条
  • [1] Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression
    Reif, Andreas
    Bitter, Istvan
    Buyze, Jozefien
    Cebulla, Kerstin
    Frey, Richard
    Fu, Dong-Jing
    Ito, Tetsuro
    Kambarov, Yerkebulan
    Llorca, Pierre-Michel
    Oliveira-Maia, Albino J.
    Messer, Thomas
    Mulhern-Haughey, Siobhan
    Rive, Benoit
    von Holt, Christian
    Young, Allan H.
    Godinov, Yordan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (14): : 1298 - 1309
  • [2] Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression
    Mcintyre, Roger S.
    Bitter, Istvan
    Buyze, Jozefien
    Fagiolini, Andrea
    Godinov, Yordan
    Gorwood, Philip
    Ito, Tetsuro
    Oliveira-Maia, Albino J.
    Vieta, Eduard
    Werner-Kiechle, Tamara
    Young, Allan H.
    Reif, Andreas
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2024, 85 : 58 - 65
  • [3] COST EFFICIENCY OF ESKETAMINE NASAL SPRAY VERSUS STANDARD OF CARE FOR TREATMENT RESISTANT DEPRESSION
    Desai, U.
    Kirson, N. Y.
    Guglielmo, A.
    Le, H.
    Spittle, T.
    Tseng-Tham, J.
    Shawi, M.
    Sheehan, J. J.
    [J]. VALUE IN HEALTH, 2019, 22 : S227 - S228
  • [4] Esketamine Nasal Spray (Spravato) for Treatment-Resistant Depression
    Chaplin, Steve
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2019, 61 (1569): : 54 - 56
  • [5] Esketamine nasal spray approved for treatment-resistant depression
    Traynor, Kate
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (09) : 573 - 573
  • [6] Esketamine Nasal Spray Effective in Treatment-Resistant Depression
    Slomski, Anita
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (04): : 296 - 296
  • [7] Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression
    Desai, Urvi
    Kirson, Noam Y.
    Guglielmo, Andrea
    Le, Hoa H.
    Spittle, Timothy
    Tseng-Tham, Joshua
    Shawi, May
    Sheehan, John J.
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (05) : 393 - 407
  • [8] Barriers to Esketamine Nasal Spray Treatment Among Adults With Treatment-Resistant Depression
    Joshi, Kruti
    Liberman, Joshua N.
    Parab, Purva
    Darer, Jonathan D.
    Harding, Lisa
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2024, 85 (02)
  • [9] Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States
    Ross, Eric L.
    Soeteman, Djora, I
    [J]. PSYCHIATRIC SERVICES, 2020, 71 (10) : 988 - 997
  • [10] In treatment-resistant depression, adding esketamine nasal spray to an oral antidepressant improved symptoms at 28
    Pal, Hemraj
    [J]. ANNALS OF INTERNAL MEDICINE, 2019, 171 (06) : JC33 - JC33
12345